Table 1.
Baseline characteristics
| Author, year | Study name | Number of patients (RM/SoC) | Follow-up (months) | Age (mean ± SD) | Male (%) | Mean LVEF (% mean ± SD) | Ischemic (%) | NYHA class (% I, II, III, IV) | ACEi/ARB (%) | Beta blocker (%) | MRA (%) | Diuretic (%) | Mortality | HF hospitalization |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraham, 2016 | CHAMPION |
550 (270/280) |
18 | 61.6 ± 13 | 72.5 | 78% with EF < 40%1 | 59 | III (0, 0, 100, 0) | 76 | 89 | 43 | 92 | x | x |
| Adamson, 2011 | REDUCEhf |
400 (202/198) |
12 | 55 ± 15 | 68.5 | 23% | 45 | II–III (0, 53, 47, 0) | 92 | 96 | N/A | 93 | x | x |
| Bohm, 2016 | OptiLink HF |
1002 (505/497) |
23 | 66.3 ± 10 | 79.7 | 26.7% | 54 | II–III (0, 19, 81, 0) | 93 | 93 | 69 | 95 | x | x |
| Boriani, 2017 | MORE CARE |
865 (437/428) |
24 | 66.5 ± 11 | 76.0 | 27.3% | 43 | II–IV2 | 82 | 89 | 32 | 92 | x | x |
| Bourge, 2008 | COMPASS-HF |
274 (134/140) |
6 | 58 ± 14 | 65.0 | Not reported3 | 47 | III–IV (0, 0, 84, 16) | 85 | 83 | N/A | 93 | x | x |
| Domenichini, 2016 | LIMIT-CHF |
80 (41/39) |
12 | 67.9 ± 11 | 94.0 | 28.3% | 78 | II–III | 95 | 90 | 66 | 81 | x | x |
| Hindricks, 2014 | IN TIME |
664 (333/331) |
11 | 65.5 ± 9.3 | 80.7 | 26% | 70 | II–III (0, 45, 55, 0) | 92 | 91 | N/A | 95 | x | |
| Landolina, 2012 | EVOLVO |
200 (99/101) |
16 | 67.5 | 78.5 | 30.5% | 38 | I–III (11, 72, 17, 0) | 90 | 84 | N/A | 91 | x | |
| Luthje, 2015 | N/A |
176 (87/89) |
15 | 65.9 ± 12 | 77.3 | 32% | 90 | I–IV (11, 46, 41, 2) | N/A | N/A | N/A | N/A | x | x |
| Morgan, 2017 | REM HF |
1650 (824/826) |
34 | 69.5 ± 10 | 85.8 | 29.9% | 68 | II–IV (0, 71, 29, 0.1) | 91 | 91 | 52 | 77 | x | |
| Van Veldhuisen, 2011 | DOT-HF |
335 (168/167) |
15 | 64 ± 10 | 86.0 | 25% | 56 | I–IV (3, 60, 36, 1) | 85 | 92 | N/A | 90 | x | x |
N/A represents data that was not reported/unable to be identified
RM remote monitoring, SoC standard of care, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, MRA mineralocorticoid receptor antagonist, LVEF left ventricular ejection fraction, NYHA New York Heart Association, SD standard deviation, HF heart failure
178% of patients had LVEF less than 40%
263% of patients were NYHA class III or IV at enrollment
3Mean LVEF not reported, but included both HFrEF and HFpEF